SCHEMBL29324075

SCHEMBL29324075

C[C@H]1CC(C(=O)c2ccc(Br)cc2)C(=O)N(C(=O)OC(C)(C)C)C1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 5/20 0.39
RORC P51449 2/20 0.38
KDM4E B2RXH2 2/20 0.37
USP30 Q70CQ3 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
SETD7 Q8WTS6 2/20 0.35
HSD11B1 P28845 1/20 0.35
AR P10275 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
BCL2 P10415 1/20 0.34
BECN1 Q14457 1/20 0.34
FPR3 P25089 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29081580 1.00 FPR2 (0.39) FPR2RORCKDM4EUSP30SMN1; SMN2
SCHEMBL25335084 0.88 USP30 (0.37) FPR2RORCUSP30SETD7KMT2A
SCHEMBL25335082 0.88 USP30 (0.37) FPR2RORCUSP30SETD7KMT2A
SCHEMBL29081684 0.86 USP30 (0.37) RORCUSP30SMN1; SMN2KMT2APDE4A
SCHEMBL29477475 0.86 USP30 (0.37) RORCUSP30SMN1; SMN2KMT2APDE4A
SCHEMBL29082022 0.85 KMT2A (0.34) USP30SMN1; SMN2SETD7HDAC1HDAC6
SCHEMBL29081616 0.83 MEN1 (0.38) RORCUSP30HDAC1HDAC6KMT2A
SCHEMBL29347987 0.83 MEN1 (0.38) RORCUSP30HDAC1HDAC6KMT2A
SCHEMBL29082047 0.82 MEN1 (0.36) FPR2USP30HSD11B1POLBKMT2A
SCHEMBL24366289 0.80 PDE4B (0.41) HSD11B1POLBPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 FPR2 1341/4885RORC 586/4885KDM4E 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.